San Diego, April 2, 2024 – Coastar Therapeutics, a pioneering biotechnology company specializing in innovative drug and biological delivery systems, is pleased to announce a strategic collaboration with SOHM, Inc. (OTC PINK: SHMN), a biopharmaceutical company focused on gene editing technologies. This partnership aims to advance genome editing by combining Coastar’s proprietary erythrocyte-derived membrane gene carriers with SOHM’s ABBIE (A Binding Based Integrase Enzyme) genome editing technology.  

Gene editing, particularly through CRISPR-Cas9 and integrase-based systems, has transformed the landscape of genetic research and therapeutics. However, the safe and efficient delivery of gene editing tools remains a critical challenge. Through this collaboration, Coastar Therapeutics and SOHM aim to develop a novel platform for precise and targeted genome editing, enhancing the potential of gene therapy and regenerative medicine.  

“Our red blood cell membrane-derived carriers provide an innovative and biocompatible solution for delivering therapeutic payloads,” said Eddie Chung, CEO of Coastar Therapeutics. “We are excited to integrate our cutting-edge delivery technology with SOHM’s ABBIE system, a novel gene editing platform that offers enhanced precision. This collaboration represents an important step forward in making genome editing more efficient and clinically viable.”  

Coastar’s red blood cell membrane-derived carriers have demonstrated immense potential in protecting and efficiently delivering gene-editing tools into cells. Their biocompatibility, stability, and immune-evasive properties make them an ideal vehicle for in vivo and in vitro gene editing applications. By integrating these carriers with SOHM’s ABBIE fusion protein-based system, the two companies aim to create a scalable and versatile gene editing platform that can be used across multiple cell types and tissues.  

Dr. David Aguilar, COO of SOHM, added, “Coastar’s novel carriers offer a unique and promising approach to enhance the delivery of our ABBIE protein complexes. This collaboration aligns perfectly with our mission to develop innovative gene editing technologies that can be applied in a wide range of therapeutic applications. We are excited about the potential impact this collaboration can have on the field of genome editing.” 

Both Coastar and SOHM share a vision of transforming gene editing technologies to improve patient outcomes. This collaboration marks a significant advancement toward safer, more precise, and more accessible genetic medicine, unlocking new possibilities for gene therapy, regenerative medicine, and synthetic biology.  

About Coastar Therapeutics  

Coastar Therapeutics is a biotechnology company dedicated to developing breakthrough delivery systems for gene and drug therapies. Using proprietary erythrocyte-derived nanocarriers, Coastar aims to overcome current limitations in gene therapy delivery and revolutionize the way genetic medicines are administered. The company is committed to advancing safe, effective, and targeted delivery technologies to improve patient care and clinical outcomes.  

About SOHM, Inc. 

SOHM, Inc. is a biopharmaceutical company specializing in gene editing technologies for research, synthetic biology, and therapeutic applications. Focused on precision medicine, SOHM is developing next-generation gene editing tools that offer improved accuracy and efficiency for treating genetic disorders. Through strategic partnerships and cutting-edge research, SOHM is committed to advancing the future of gene therapy.